STEPPING IN: Keith Cochrane, former CEO of Weir Group and independent nonexecutive director at Carillion, will take over as interim chief. Picture: BLOOMBERG/CHRIS RATCLIFFE
STEPPING IN: Keith Cochrane, former CEO of Weir Group and independent nonexecutive director at Carillion, will take over as interim chief. Picture: BLOOMBERG/CHRIS RATCLIFFE

Shire, Roche in court fight

Pharmaceutical group Shire has obtained a preliminary injunction in a Hamburg court against rival Roche over its haemophilia drug emicizumab, alleging incomplete and misleading statements surrounding the treatment.

Roche is hoping to win a slice of the US$11bn/year haemophilia drug market with the drug, also known as ACE910, which has been designed to compete with more traditional treatments from Novo Nordisk and Shire — Reuters

Carillion misses profit goal

Carillion’s stock price plunged the most on record after the British construction company said first-half profit will be lower than expected, dividend payments will be suspended and CEO Richard Howson has stepped down.

Cash flow from some projects has deteriorated, and the board will review all its major contracts with the help of KPMG, Carillion said in a statement. The company will also undertake a "comprehensive review" of the business and capital structure, with all options to boost the stock price under consideration. Carillion is looking to raise £125m from exiting some businesses and markets over the next 12 months, and more cost savings will be found — Bloomberg

Please sign in or register to comment.